NCT05740449 - HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Biotech Hunter

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2029

Study Completion Date

October 1, 2029

Conditions

Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Interventions

DRUG

Decitabine

intravenous

DRUG

Venetoclax

oral

DRUG

Navitoclax

oral

DRUG

intrathecal chemotherapy

IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement

Trial Locations (1)

3584CS

Princess Máxima Center for Pediatric Oncology, Utrecht